Emerging Diseases: Disruptive, Commercially Risky, But GSK Has A Solution
Executive Summary
GlaxoSmithKline PLC has offered up its new Maryland vaccine research and development center, and its scientists, under the company's proposal to establish a global collaboration for the pursuit of products that are commercially risky, but necessary to address emerging infectious diseases, before a public health crisis strikes.
You may also be interested in...
Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
Bringing drugs and vaccines for emerging infectious diseases to the marketplace requires playing the long game and collaborations if efforts are going to be successful.
GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika
GlaxoSmithKline PLC and the National Institute of Allergy and Infectious Diseases have entered into a partnership to develop a Zika vaccine based on the company's self-amplifying mRNA technology – a collaboration that could yield biomedical research and development benefits far beyond the current epidemic.
Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials
Cash borrowed from various US government programs, including the Ebola response, is enough to get at least two Phase I Zika vaccine trials underway, but those funds won't carry the efficacy studies – the preparations of which must get off the ground next month. So Congress needs to allocate new dollars within the next few weeks or the Phase II trials will be in jeopardy, Anthony Fauci, the nation's top infectious disease official, told Scrip.